Myriad Genetics (MYGN) Accumulated Expenses (2010 - 2026)

Myriad Genetics (MYGN) has reported Accumulated Expenses for 17 consecutive years, with $90.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 19.27% year-over-year to $90.5 million; the TTM figure through Mar 2026 stood at $90.5 million (down 19.27% YoY), while the FY2025 annual figure was $96.9 million, down 18.57% from the prior year.
• Accumulated Expenses declined to $90.5 million in Q1 2026 per MYGN's latest filing, from $96.9 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $164.3 million in Q2 2023 and bottomed at $84.4 million in Q2 2022.
• Historically, Accumulated Expenses has averaged $109.0 million across 5 years, with a median of $100.6 million in 2025.
• Annual changes were most pronounced in 2022 — Accumulated Expenses sank 47.73% — and 2023, when it surged 94.67%.
• Myriad Genetics' Accumulated Expenses stood at $94.3 million in 2022, then advanced by 20.78% to $113.9 million in 2023, then advanced by 4.48% to $119.0 million in 2024, then decreased by 18.57% to $96.9 million in 2025, then fell by 6.6% to $90.5 million in 2026.
• Business Quant data shows MYGN's Accumulated Expenses at $90.5 million in Q1 2026, $96.9 million in Q4 2025, and $108.3 million in Q3 2025.